Supplemental new drug application
![FDA Acceptance of sNDA for Fifth BRUKINSA Indication Announced by BeiGene](https://pharmtales.com/wp-content/uploads/2023/07/FDA-Acceptance-of-sNDA-for-Fifth-BRUKINSA-Indication-Announced-by-BeiGene.jpg)
FDA Acceptance of sNDA for Fifth BRUKINSA Indication Announced by BeiGene
SG Tylor
Source – Beigene BeiGene, a prominent global biotechnology company, made a groundbreaking announcement today. The US Food and Drug Administration ...
![Zanubrutinib Plus Obinutuzumab for R/R Follicular Lymphoma Receives FDA Acceptance of sNDA](https://pharmtales.com/wp-content/uploads/2023/07/Zanubrutinib-Plus-Obinutuzumab-for-R_R-Follicular-Lymphoma-Receives-FDA-Acceptance-of-sNDA.jpg)
Zanubrutinib Plus Obinutuzumab for R/R Follicular Lymphoma Receives FDA Acceptance of sNDA
SG Tylor
Source – BeiGene BeiGene has announced that the FDA has accepted a supplemental new drug application (sNDA) for the combination ...